Synergistic drug–cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity

Cosgrove, B; King, B; Hasan, M; Alexopoulos, L; Farazi, P; Hendriks, B; Griffith, L; Sorger, P; Tidor, B; Xu, J; Lauffenburger, D

dc.contributor.author	Cosgrove, B	en
dc.contributor.author	King, B	en
dc.contributor.author	Hasan, M	en
dc.contributor.author	Alexopoulos, L	en
dc.contributor.author	Farazi, P	en
dc.contributor.author	Hendriks, B	en
dc.contributor.author	Griffith, L	en
dc.contributor.author	Sorger, P	en
dc.contributor.author	Tidor, B	en
dc.contributor.author	Xu, J	en
dc.contributor.author	Lauffenburger, D	en
dc.date.accessioned	2014-03-01T01:58:08Z
dc.date.available	2014-03-01T01:58:08Z
dc.date.issued	2009	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/28653
dc.subject	Adverse Drug Reaction	en
dc.subject	Drug Development	en
dc.subject	hepg2 cell	en
dc.subject	Information Theory	en
dc.subject	Partial Least Square	en
dc.subject	Regression Model	en
dc.subject	Drug Induced Liver Injury	en
dc.subject	High Throughput	en
dc.subject	Information Theoretic	en
dc.title	Synergistic drug–cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity	en
heal.type	journalArticle	en
heal.identifier.primary	10.1016/j.taap.2009.04.002	en
heal.identifier.secondary	http://dx.doi.org/10.1016/j.taap.2009.04.002	en
heal.publicationDate	2009	en
heal.abstract	Idiosyncratic drug hepatotoxicity represents a major problem in drug development due to inadequacy of current preclinical screening assays, but recently established rodent models utilizing bacterial LPS co-administration to induce an inflammatory background have successfully reproduced idiosyncratic hepatotoxicity signatures for certain drugs. However, the low-throughput nature of these models renders them problematic for employment as preclinical screening assays. Here, we present	en
heal.journalName	Toxicology and Applied Pharmacology	en
dc.identifier.doi	10.1016/j.taap.2009.04.002	en